Peter P. Stein

TL;DR: The primary aim is to compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control on metformin monotherapy.

TL;DR: To assess the efficacy and safety of a 24‐week treatment with sitagliptin, a highly selective once‐daily oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control while on glimepiride alone or in combination with metformin.

TL;DR: After 24 weeks, sitagliptin added to pioglitazone therapy was associated with significant reductions compared with placebo in HbA(1c), and the Homeostasis Model Assessment beta-cell function and insulin-resistance indexes; the proinsulin/ insulin ratio; the Quantitative Insulin Sensitivity Check Index.

TL;DR: Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well-tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks.

TL;DR: The safety of sitagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency or patients with end‐stage renal disease on dialysis was assessed.